News Headlines

  1. Inovio And Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection

    Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Korean Ministry of Food and Drug Safety approved the initiation of a study to evaluate GLS-5300, Inovio’s vaccine against the MERS virus (Middle East Respiratory Syndrome), in a phase 1/2a trial.

  2. Fate Therapeutics Initiates Phase 2 PROTECT Study Of ProTmune™ For Prevention Of Acute Graft-Versus-Host Disease

    Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company initiated enrollment in the Phase 2 stage of PROTECT, a combined open-label Phase 1 / blinded Phase 2 clinical trial of ProTmune™ for the prevention of acute graft-versus-host disease (GvHD) in patients with hematologic malignancies undergoing matched unrelated donor hematopoietic cell transplantation (HCT).

  3. U.S. FDA Grants Fast Track Designation To Pluristem's PLX-PAD For The Treatment Of Critical Limb Ischemia (CLI)

    Pluristem Therapeutics, Inc., a leading developer of placenta-based cell therapy products, recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s ongoing Phase III study of PLX-PAD cells for the treatment of Critical Limb Ischemia (CLI) in patients ineligible for revascularization.

  4. Nabriva Therapeutics Announces Positive Topline Results From Global, Phase 3 Clinical Trial Evaluating IV And Oral Lefamulin For The Treatment Of Community-Acquired Bacterial Pneumonia

    Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced positive topline results from the lefamulin evaluation against pneumonia (LEAP 1) trial, which evaluated the safety and efficacy of intravenous (IV) to oral lefamulin in patients with community-acquired bacterial pneumonia (CABP).

  5. Sanofi And Regeneron Announce Positive Study Results For Dupixent (dupilumab) In Patients With Moderate-To-Severe Atopic Dermatitis

    Sanofi and Regeneron Pharmaceuticals, Inc. announced recently positive results from the Phase 3 CAFÉ study of Dupixent (dupilumab) in adults with moderate-to-severe atopic dermatitis (AD) who are inadequately controlled with or intolerant to the broad immunosuppressant drug cyclosporine A (CSA), or when this treatment is medically inadvisable.

  6. Phrixus Pharmaceuticals Announces Phase 2 Clinical Trial Of Poloxamer 188 NF In Non-Ambulatory Patients With Duchenne Muscular Dystrophy

    Phrixus Pharmaceuticals, Inc. (“Phrixus”), a company focused on therapies for Duchenne muscular dystrophy (DMD) and heart failure, today announced agreements with several DMD patient organizations and Cincinnati Children’s Hospital to conduct a first clinical trial of Carmeseal-MD™’s, active pharmaceutical ingredient Poloxamer 188 NF (P-188 NF), for the treatment of DMD in non-ambulatory patients.

  7. Bracket Welcomes New Chief Technology Officer Sam Whitaker

    Bracket, a leading clinical trial technology and specialty services provider, recently welcomed Sam Whitaker as Chief Technology Officer (CTO) to its growing team.

  8. TransPerfect Life Sciences Announces Trial Interactive 9.1 Release And Other Upcoming Innovations

    TransPerfect Life Sciences, a leading provider of services and technologies to support global clinical trials, recently announced the release of Trial Interactive 9.1, the latest version of its award-winning e-clinical platform.

  9. OncoMed Doses First Patient With GITRL-Fc In Phase 1a Clinical Trial

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, announced today that the first patient has been dosed in the company’s Phase 1a clinical trial of GITRL-Fc (OMP-336B11).

  10. Daily Blood Glucose Measures In Phase 3 Clinical Trials Demonstrated Better Stability With Sanofi's Toujeo® Vs. Insulin Glargine 100 Units/mL

    In a new analysis of late stage clinical trials,2-4 adults with type 2 diabetes treated with Sanofi's Toujeo® (insulin glargine 300 Units/mL, Gla-300) achieved better blood glucose stability than those on insulin glargine 100 Units/mL (Lantus®, Gla-100)